Redefining the Diagnosis and Therapy of COPD: Lessons from COPDGene, GOLD Reports, and Precision Medicine

 

 

PROGRAM OVERVIEW

Chronic obstructive pulmonary disorder (COPD) is a complex and heterogeneous disease that is associated with significant morbidity and mortality. Despite efforts to standardize the diagnosis, treatment, and management of this progressive disease, clinical practice has consistently underdiagnosed and undertreated this condition. As a result, patients with COPD continue to be associated with a poor quality of life, and there has remained an unmet need to improve its continuum of care. Recent data have shown that, using new criteria and methodologies, the definition of COPD can be broadened to include patients who would have been excluded from a previously characterized definite diagnosis. In addition, earlier treatment of such patients with pharmacologic, non-pharmacologic, and preventive strategies would be of benefit in reducing the burden of symptoms. Furthermore, implementation of updated guidelines and novel precision medicine–based approaches to individualize management of diverse patients with COPD will also be critical to improving outcomes. This continuing education program will clarify the clinical implications of new perspectives in the diagnosis, treatment, and management of this complicated disease.

FACULTY

Gerard Criner, MD, FACP, FACCP​
Professor of Medicine​
Chair, Department of Thoracic Medicine & Surgery ​
Lewis Katz School of Medicine​
Temple University Co-Director, Center for Inflammation ​and Lung Research
Medical Director, Pulmonary Service Line​
Temple University Hospital ​
Philadelphia, Pennsylvania

 

Fernando J. Martinez, MD, MS
Chief, Division of Pulmonary and Critical Care Medicine​
NewYork-Presbyterian/Weill Cornell Medical Center​
New York, New York

 

 

Ruth Tal-Singer, PhD 
President and Chief Scientific Officer
COPD Foundation
Washington, District of Columbia
President, TALSi Translational Medicine Consulting, LLC
Greater Philadelphia, Pennsylvania

 

Release date: November 30, 2020
Expiration date: November 30, 2021
Estimated time to complete activity: 1 hour(s)

 

TARGET AUDIENCE

This educational activity has been designed for pulmonologists and other clinicians involved in the management of patients with COPD.

LEARNING OBJECTIVES

Upon completion of this educational activity, participants will be able to:

  • Identify clinical, functional, and radiological characteristics that can facilitate earlier COPD diagnosis and recognition of those who can benefit from available therapies​
  • Recognize the importance of smoking cessation, early treatment, and other prevention approaches in alleviating the burden of COPD​
  • Apply precision medicine–based approaches and current GOLD strategy to improve individualized treatment of COPD​
  • Describe the ongoing evolution of COPD diagnosis and its management in the era of COVID-19
DIRECTIONS TO LEARNER

There are no fees for participating and receiving CME credit for this activity. During the period of November 30, 2020 through November 30, 2021, participants must:

  • Read the learning objectives and faculty disclosures
  • Complete the pretest
  • Study the educational activity
  • Complete the posttest and the evaluation form

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed posttest with a score of 70% or better.

MEDIA

Internet

ACCREDITATION STATEMENT

Integrity Continuing Education, Inc is accredited with commendation by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION

Integrity Continuing Education, Inc. designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s). Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTACT INFORMATION

For information about ACCME accreditation of this activity, please contact Integrity Continuing Education at (855) 835-4004 or cme@integrityce.com.

DISCLOSURE OF CONFLICTS OF INTEREST

Integrity Continuing Education requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Integrity Continuing Education for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The following faculty/planners reported the financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of these CME activities:

Gerard Criner, MD, FACP, FACCP
Consulting Fees:Amgen, AstraZeneca, Boehringer Ingelheim, Broncus Medical, CSA Medical, Eolo Medical, Gala Therapeutics, GlaxoSmithKline, Helios Medical, Merck, Medtronic, Mereo BioPharma, NGM Biopharmaceuticals, Novartis, Olympus, PulmonX, Philips Respironics, Respivant Sciences, The Implementation Group, Verona Pharma ​

Fernando J. Martinez, MD, MS
Consulting Fees: AstraZeneca, Boehringer Ingelheim, CSL Behring, Genentech, GlaxoSmithKline, Sanofi/Regeneron​
Contracted Research: Afferent/Merck, Bayer, Biogen, Gilead, GlaxoSmithKline, Respivant Science, ProMedior/Roche, Veracyte​

Ruth Tal-Singer, PhD 
Former employee and current shareholder of GSK and reports personal fees from VOCALISHEALTH, ImmunoMet, and Ena Respiratory

Patima Tanapat, PhD, hereby states that she or her spouse/life partner do not have financial relationships to products of devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The Integrity CE planners and managers have nothing to disclose.

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Integrity Continuing Education, Inc. and AstraZeneca do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

PRIVACY POLICY

When you participate in an online educational activity sponsored by Integrity Continuing Education, Inc., you will be asked for your name, degree(s), affiliation(s), street address, telephone number, fax number, and…(continued)

MINIMUM SYSTEM REQUIREMENTS

Minimum Processor: Intel Pentium 4, 2.33 + GHz (or equivalent)
Operating Systems: Windows XP, Windows 2000, Windows Vista, Windows 7, Windows 10, and Mac OS
Plug-in: Adobe® Flash® Player 10

  • Adobe® Flash® Player 10 plug-in should be downloaded
  • Click on the “Agree and install now” button after unchecking the optional McAfee Security Scan Plus

For optimal performance, the use of Internet Explorer below 8 is not recommended.
For a full listing of recommended operating systems, browsers, and system configurations, please click on the link below

Click here for more information on minimum system requirements.

DISCLAIMER

The information provided in this activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient’s medical condition.

PROVIDER STATEMENT

Provided by Integrity Continuing Education, Inc.

SUPPORTER ACKNOWLEDGEMENT

Supported by an educational grant from AstraZeneca.

Continue to Pretest